Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25746
Abstract: We evaluated bone marrow minimal residual disease (MRD) negativity in 44 patients with light chain (AL) amyloidosis using next generation flow cytometry (sensitivity ≥1 × 10−5; median events analyzed: 8.7 million, range: 4.8 to 9.7 million). All… read more here.
Keywords: minimal residual; mrd; response; mrd negative ... See more keywords
Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-020-00579-0
Abstract: Purpose of Review This review will discuss the data and controversies related to HCT in the front-line and relapsed/refractory setting in the context of newly available targeted immunotherapies. Recent Findings Recent studies in adult Ph-negative… read more here.
Keywords: relapsed refractory; mrd negative; front line; hct ... See more keywords
Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70175
Abstract: In March 2024, ponatinib received accelerated FDA approval for the treatment of newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy based on the Phase 3 PhALLCON study (NCT03589326), which demonstrated a… read more here.
Keywords: phallcon study; phallcon; mrd negative; population ... See more keywords
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-11-883710
Abstract: Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors… read more here.
Keywords: car cell; cell therapy; mrd negative; cell ... See more keywords
Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-128399
Abstract: Patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) usually have a very poor prognosis and an expected survival of less than 6 months.The complete remission (CR) rates in the setting of the first salvage chemotherapy… read more here.
Keywords: positive relapse; mrd positive; group; mrd negative ... See more keywords
Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2255
Abstract: Introduction: Iberdomide (IBER) is an oral CELMoD™ agent with optimized cereblon binding leading to improved direct antitumor and immunostimulatory effects versus immunomodulatory drug (IMiD®) agents. Preliminary findings from the phase 1/2 CC-220-MM-001 trial (NCT02773030) demonstrated… read more here.
Keywords: 001 trial; mrd negativity; 220 001; mrd negative ... See more keywords
Maintenance therapy discontinuation for patients diagnosed with multiple myeloma without high-risk features in minimal residual disease (MRD) negative remission: An interim analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2261
Abstract: Background: Continuous maintenance therapy is a standard practice for many physicians treating multiple myeloma (MM). Lenalidomide maintenance treatment has been shown to improve progression-free survival (PFS) and, in some studies, overall survival (Richardson et. al.… read more here.
Keywords: multiple myeloma; maintenance; therapy; mrd negative ... See more keywords
Blinatumomab plus dasatinib in a dialysis-dependent patient with ph-positive B-ALL: Durable MRD-negative remission
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6874
Abstract: Background & Rationale:Philadelphia-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL) accounts for ~20–30% of adult ALL. Contemporary frontline regimens combine a BCR-ABL1 tyrosine-kinase inhibitor (TKI) with the CD19-directed bispecific T-cell engager blinatumomab. Patients with end-stage renal… read more here.
Keywords: mrd negative; dasatinib; remission; dialysis ... See more keywords
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021005039
Abstract: Hairy cell leukemia variant (HCLv) responds poorly to purine analog monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rate, but long-term outcomes are unknown. We report final results of a phase II study of CDAR… read more here.
Keywords: rituximab; long term; cell leukemia; mrd negative ... See more keywords
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2025.25142
Abstract: BACKGROUND The phase 3 PERSEUS trial demonstrated superior efficacy of daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d) induction/consolidation followed by DR maintenance (DVRd/DR) vs VRd induction/consolidation followed by R maintenance (VRd/R) in transplant-eligible… read more here.
Keywords: negative status; maintenance; mrd negative; cost per ... See more keywords
Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.776920
Abstract: Objective To explore the prognostic significance of the stage at which a minimal residual disease (MRD)-negative status is achieved for patients with newly diagnosed multiple myeloma (NDMM) who received autologous hematopoietic stem cell transplantation (ASCT).… read more here.
Keywords: mrd negative; stage; three groups; groups reached ... See more keywords